Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Takeda Pharmaceutical Ltd ADR (NY: TAK ) 14.33 -0.10 (-0.69%) Official Closing Price Updated: 7:00 PM EDT, Oct 7, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Takeda Pharmaceutical Ltd ADR < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization October 04, 2024 Johnson & Johnson has discontinued its Phase 2 study of mosnodenvir, an investigational antiviral candidate for dengue prevention, as part of a strategic shift in its R&D portfolio. Final efficacy data... Via Benzinga Takeda Receives Approval for FRUZAQLA (fruquintinib) in Japan for the Treatment of Unresectable Advanced or Recurrent Colorectal Cancer September 24, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire HUTCHMED Announces Japan Approval for FRUZAQLA® (fruquintinib) Received by Takeda September 24, 2024 From HUTCHMED (China) Limited Via GlobeNewswire Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut September 20, 2024 Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment. Via MarketBeat Topics Economy Exposures Interest Rates Takeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024 September 19, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships to Further Drive Health Impact in 93 Countries September 18, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines September 10, 2024 Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential. Via Benzinga Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst September 09, 2024 HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... Via Benzinga Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production September 06, 2024 Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. Via Benzinga Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues August 12, 2024 FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient... Via Benzinga Exposures Product Safety New Study Reveals How Classical Music Could Revolutionize Depression Care August 12, 2024 In a groundbreaking study, Chinese scientists have revealed that classical music could be a powerful tool in the fight against treatment-resistant depression, a condition that affects nearly 50% of... Via PressReach Exposures Product Safety Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday? August 07, 2024 Takeda Pharmaceutical stock rises following European Commission approval of Adzynma for treating ADAMTS13 deficiency in cTTP patients. Adzynma is the first enzyme replacement therapy in the EU for this... Via Benzinga Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP) August 07, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024 July 31, 2024 Takeda Pharmaceutical just reported results for the first quarter of 2024. Via InvestorPlace Takeda Announces First Quarter FY2024 Results - Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage Pipeline July 31, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire 3 Biotech Stocks to Buy on the Dip: July 2024 July 29, 2024 Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip. Via InvestorPlace Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation July 24, 2024 Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK... Via Benzinga Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst July 09, 2024 Eli Lilly's acquisition of Morphic highlights strategic expansion in Immunology, targeting α4β7 for ulcerative colitis and Crohn's disease treatments. Goldman Sachs notes the deal's potential to... Via Benzinga Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma July 06, 2024 Samsung Biologics, a Korean CDMO, signed a $1.06 billion agreement to provide manufacturing services for an unnamed US pharma. The agreement is the largest that Samsung Bio has made since it was... Via Talk Markets Blackstone Nears $2.2B Deal For Sale Of Japanese Supplement Maker Alinamin: Report July 02, 2024 Blackstone Inc. is reportedly finalizing a deal to sell Alinamin Pharmaceutical to MBK Partners for $2.17 billion. Blackstone acquired Alinamin from Takeda in 2020. Via Benzinga Protagonist Therapeutics Surges On Plans To Join S&P SmallCap 600 June 28, 2024 Protagonist Therapeutics will join the SmallCap 600 on Wednesday. Via Investor's Business Daily Topics Stocks Exposures US Equities Takeda Announces New Assignments of Directors June 26, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies June 24, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia June 22, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer June 21, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire HUTCHMED Announces European Commission Approval for FRUZAQLA® (fruquintinib) Received by Takeda June 21, 2024 From HUTCHMED (China) Limited Via GlobeNewswire NextEra Energy, Lennar And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session June 18, 2024 Via Benzinga Takeda Presents Long-Term Data from Phase 3 ADVANCE-CIDP 3 Clinical Trial of HYQVIA® in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) at PNS Annual Meeting June 18, 2024 From Takeda Pharmaceutical Company Limited Via Business Wire Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session June 17, 2024 Via Benzinga What's Going On With Ovid Therapeutics After Takeda's Two Phase 3 Epilepsy Studies Fail? June 17, 2024 Takeda Pharmaceutical reveals Phase 3 study data for Soticlestat (TAK-935) in treating Dravet and Lennox-Gastaut syndromes. In 2021, Ovid Therapeutics out licensed the drug. Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 16 17 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.